A phase III study to evaluate the safety and efficacy of Cyclobenzaprine (TNX-102 SL) in patients with post traumatic stress disorders

Trial Profile

A phase III study to evaluate the safety and efficacy of Cyclobenzaprine (TNX-102 SL) in patients with post traumatic stress disorders

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Sep 2016 New trial record
    • 29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, the company expects to initiate this study later in the year 2017.
    • 29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study will support the planned New Drug Application (NDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top